COVID-19 researchGene: PSMA3
agree with all the Amber genes
Created: 25 Sep 2019, 1:49 p.m. | Last Modified: 25 Sep 2019, 1:49 p.m.
Panel Version: 1.115
I think CANDLE should be green
Created: 26 Sep 2019, 12:43 p.m. | Last Modified: 26 Sep 2019, 12:43 p.m.
Panel Version: 1.127
The amber genes are covered on our targeted exome, we feel that these should be covered in the testing
Created: 25 Sep 2019, 1:44 p.m. | Last Modified: 25 Sep 2019, 1:44 p.m.
Panel Version: 1.114
Not described as associated with a stand-alone disorder (though variants may modulate disease severity in CANDLE/PRAAS patients)
Created: 29 Jun 2018, 3:08 p.m.
Gene was flagged as requiring further clinical input from the Immunology Test Group, but no additional information was submitted to support the Green rating. In view of a lack of clear evidence the current recommendation is Amber.
Created: 12 Nov 2019, 5:03 p.m. | Last Modified: 12 Nov 2019, 5:03 p.m.
Panel Version: 1.137
?Proteasome-associated autoinflammatory syndrome 1, digenic. Two unrelated children het
for this and another gene (PSMB8) hence ?digenic - amber on association
Created: 26 Sep 2019, 3:58 p.m. | Last Modified: 26 Sep 2019, 3:58 p.m.
Panel Version: 1.130
Comment on list classification: Changed rating from Red to Amber to reflect the agreed rating agreed by the GMS Immunology Specialist Test Group, but flagged for further follow up with the Immunology Test Group due to the subsequent conflicting review. Evidence /opinion needs consensus before upgrading to Green
Created: 25 Sep 2019, 3:12 p.m. | Last Modified: 26 Sep 2019, 1:03 p.m.
Panel Version: 1.127
Gene rating submitted by Tracy Briggs, David Gokhale and Abigal Rousseau on behalf of North West GLH for the GMS Immunology specialist test group. Although discussed with the GMS Immunology Specialist Test Group during webex call 28th March 2019 to rate Amber in the confirmed follow up email on 20th June North West GLH reasserted that PSMA3 should be Green
Created: 25 Sep 2019, 3 p.m. | Last Modified: 26 Sep 2019, 11:17 a.m.
Panel Version: 1.126
Gene rating submitted by Kimberly Gilmour and Austen Worth on behalf of London North GLH for the GMS Immunology specialist test group. As discussed with the GMS Immunology Specialist Test Group during webex call 28th March 2019 and confirmed in follow up email 6th September the Specialist Test Group all agreed there is only enough evidence to rate this gene Amber
Created: 25 Sep 2019, 3 p.m. | Last Modified: 25 Sep 2019, 3 p.m.
Panel Version: 1.116
Comment on publications: PMID:26524591 suggested by Tracy Briggs (NWGLH) on behalf of the Specialist Test Group to support inclusion of this gene on the panel and a Green rating. Flagged for further discussion with the Specialist Test Group as conflicts with the Amber rating agreed in the webex 28th March 2019
Created: 15 Aug 2019, 4:20 p.m. | Last Modified: 12 Sep 2019, 3:32 p.m.
Panel Version: 1.55
Comment on list classification: External expert review notes Red status due to no evident link to immunodeficiency, rather variants are modulators rather than a direct gene-disease association, so I have kept this gene Red on this panel until further evidence. Referred back to Victorian Clinical Genetics Services for evidences.
Created: 4 Jul 2018, 5:59 p.m.
Comment on list classification: This gene was absent from the original PanelApp PID panel dataset (review April 2018). However it was listed in external expert immunodeficiency diagnostic gene list from Victorian Clinical Genetics Services. In this combined PID panel, this gene has been rated as AMBER and needs further curational review to assess pertinence prior to v1. No disorder or MOI was listed in the submitted list.
Created: 26 Jun 2018, 12:45 p.m.
gene: PSMA3 was added gene: PSMA3 was added to Viral susceptibility. Sources: Victorian Clinical Genetics Services,North West GLH,NHS GMS,London North GLH,Expert Review Amber Mode of inheritance for gene: PSMA3 was set to Unknown Publications for gene: PSMA3 were set to 26524591 Phenotypes for gene: PSMA3 were set to CANDLE syndrome (Autoinflammation, lipodystrophy, and dermatosis syndrome)